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ported that t“It’s hard to make predictionsd
especially about the future.”dRobert Storm Petersen (1)
Predictions are even harder in medicine, when so much in-
dividual variability and system complexity occurs. Nonethe-
less, we should not shun this important task. Few imaging
modalities offer a more comprehensive phenotyping of the
heart than cardiac magnetic resonance (CMR). It is currently
the noninvasive gold standard for quantiﬁcation of car-
diac volumes and function (2), provides excellent anato-
mic depiction of cardiac structures and massesdbeneﬁting
from its unique ability to differentiate and characterize
tissuesdand has been shown to be at least as accurate as
single-photon emission tomography for myocardial ische-
mia detection (3). CMR has also been shown to detectSee page 1031myocardial ﬁbrosis and necrosis (4), microvascular obstruc-
tion and hemorrhage (5,6), and myocardial edema (7). Most
of these diagnostic capabilities have been shown to contain
prognostic information that allows for better risk assess-
ment and ensuing patient care. In this issue of the Journal,
El Aidi et al. (8) have published a systematic review of the
literature examining the prognostic ability of different infor-
mation provided by CMR in acute, chronic, and suspected
coronary artery disease (CAD). For their well-performed
work, and especially for the elegant compilation of so much
information in comprehensive tables, the authors are to be
congratulated.
Left ventricular ejection fraction (LVEF) is themost widely
used cardiac systolic performance measure. Despite having
some dependence on physiological conditions (i.e., pre-load
and afterload), its reduction below normal thresholds ex-
presses the failure of many compensatory mechanisms, and isublished in the Journal of the American College of Cardiology reﬂect the
e authors and do not necessarily represent the views of JACC or the
ollege of Cardiology.
yNational Institute of Cardiology, Rio de Janeiro, Brazil; and the zClínica
ico por Imagem (CDPI), Rio de Janeiro, Brazil. Both authors have re-
hey have no relationships relevant to the contents of this paper to disclose.related to advanced stages of most cardiac pathologies.
Deprived of its reserve, the failing heart is both unable to
respond to physiological necessities and is more susceptible to
fatal arrhythmias (9). For at least 40 years (10), LVEF, as
assessed by different invasive and noninvasive methods, has
successfully been tested for prognostication in a variety of
clinical scenarios. Accordingly, El Aidi et al. (8) have shown
that when the LVEF falls by 10%, the risk of events increases
13% to 15% in acute coronary syndromes and increases 18% to
28% in chronic or suspected CAD. CMR is the gold standard
noninvasive imaging technique to assess LVEF because of its
high accuracy in chamber volumetric measurements associ-
ated with very low measurement variability (2).
CMR can detect obstructive CAD by either inducing wall
motion abnormalities (WMA) after an adrenergic stressor
(usually dobutamine) (11) or by inducingmyocardial perfusion
gradients after a vasodilatory challenge (usually with adenosine
or dipyridamole) (3). Although one could potentially combine
WMA and perfusion assessments, this does not enhance
overall accuracy in detecting obstructive CAD (12), and in
practice, it is not usually performed. It should be noted
that vasodilators do not necessarily induce ischemia, but rather
generate perfusion imbalances between myocardial territories
as seen by signal intensity gradients during ﬁrst-pass dynamic
imaging. Because blood ﬂow distal to an obstructive lesion at
peak vasodilatory challenge may be similar to rest, using va-
sodilators for inducing WMAs have been shown to have low
sensitivity for obstructive CAD detection (13), and are rarely
used. Conversely, when true myocardial ischemia is generated
by dobutamine stress, the patient’s heart rate is frequently
higher than 150 beats/min, which, when added to the
discomfort generated by the drug, makes stress contractility
plus perfusion imaging impractical. Curiously, both WMA
and perfusion assessments appear to have similar diagnostic
accuracies, but as El Aidi et al. (8) have shown, perfusion
abnormalities appear to have greater prognostic impact
(adjusted hazard ratio [HR]: 3.02 to 7.77) than WMA
(adjusted HR: 1.87 to 2.99). The reason for this is not
completely clear, and is worthy of further scientiﬁc investiga-
tion, because this is one of the most important messages from
their work. But regardless of the methodology used for
obstructive CAD detection, one has to bear in mind that the
causa mortis is usually plaque instability leading to myocardial
infarction (MI), for which higher obstruction grades are a
major risk factor (14).Hence, prognostic information ismostly
driven by the extension ofmyocardial ischemia (directly related
to the number and location of obstructive lesions) and to
ischemia intensity (directly related to the degree of stenosis).
Perhaps the most sought for information from CMR is
myocardial ﬁbrosis, as seen by late gadolinium enhancement
(LGE). The myocardium is a densely packed cellular
structure, with aligned myocytes lying side by side and with
relatively little extracellular matrix (only approximately 25%
of the tissue). Being an extracellular agent, gadolinium has
little distribution in normal myocardium, but its concen-
tration increases greatly in necrotic or ﬁbrotic tissue. LGE
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both ischemic and nonischemic cardiomyopathies (15,16).
Because LGE can be seen with as little as 5 g of myocardial
ﬁbrosis, it is the most sensitive noninvasive method for
ﬁbrosis or necrosis detection. The presence of myocardial
LGE has been extensively shown to be associated with worse
prognosis, and not surprisingly, El Aidi et al. (8) have
conﬁrmed previous results from single studies, ﬁnding an
adjusted HR between 2.82 and 9.43 across different studies
of chronic or suspected CAD.
Regarding acute coronary syndromes, the authors present
some confusing results. Theoretically, infarct size (as seen by
CMR LGE) should be more closely related to prognosis
than acute LVEF is, because myocardial stunning may
obscure the long-term LVEF. But El Aidi et al. (8) have
found that although LVEF was an independent predictor of
major adverse cardiac events, infarct size was a predictor only
on univariate analysis. In fact, they report that CMR con-
tained no prognostic information at all regarding hard events
in acute MI, which is very unlikely, both because of physi-
ological reasons and because there is ample evidence that
LVEF measured by echocardiography is related to hard
events in the acute coronary syndrome setting (17). The
reason for the authors’ ﬁndings is the somewhat arbitrary
(although the line has to be drawn somewhere) determina-
tion that any variable that has <1,000 patients studied did
not present enough evidence for conclusions. Regardless of
the validity of this 1,000-patient threshold, this brings into
light the urgent need of CMR studies in the acute MI
setting. It would also be interesting to understand how all
CMR variables combined interact with the prognostic
models, especially using individual patient data meta-
analyses.
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